U.S., Jan. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07315087) titled 'CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases' on Dec. 18, 2025.
Brief Summary: CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Study Start Date: Jan. 01
Study Type: INTERVENTIONAL
Condition:
SLE - Systemic Lupus Erythematosus
SSc-Systemic Sclerosis
IIM- Idiopathic Inflammatory Myopathies
ANCA Associated Vasculitis (AAV)
Connective Tissue Disease-Associated Thrombocytopenia
SLE-ITP
Intervention:
BIOLOGICAL: QT-019C
universal allogeneic anti-CD19/BCMA CAR T-cells
Recruitment Status: RECRUITING
Sponsor: Ins...